Join
Live feed
·
PRReleasevia Quantisnow
Tango Therapeutics Inc. logo

Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective Response Rate in Pancreatic Cancer

ByQuantisnow·Wall Street's wire, on your screen.
TNGX· Tango Therapeutics Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track TNGX (Tango Therapeutics Inc.) and more on Quantisnow.